RESULTS	However , in preplanned analyses , overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials : in LUX-Lung 3 , median overall survival was 33.3 months ( 95 % CI 26.8-41 .5 ) in the afatinib group versus 21.1 months ( 16.3-30 .7 ) in the chemotherapy group ( HR 0.54 , 95 % CI 0.36-0 .79 , p = 0.0015 ) ; in LUX-Lung 6 , it was 31.4 months ( 95 % CI 24.2-35 .3 ) versus 18.4 months ( 14.6-25 .6 ) , respectively ( HR 0.64 , 95 % CI 0.44-0 .94 , p = 0.023 ) .\